Trial Profile

Phase 1, open-label, randomized, single-dose, 3-way crossover trial to compare the pharmacokinetics (PK) of sebetralstat following administration of ODT and the current film-coated tablets in healthy adult volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Feb 2023 Results comparing the pharmacokinetic characteristics, safety and tolerability of sebetralstat administered as orally disintegrating tablets and film coated tablets in healthy volunteers, presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
07 Nov 2022 New trial record
31 Oct 2022 According to KalVista Pharmaceuticals Media Release, KalVista recently completed a clinical trial to investigate the pharmacokinetics of the ODT.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com